ÂÜÀòÂÒÂ×

Chris Ehrlich is a seasoned executive with extensive experience in the biotechnology and therapeutics sectors. Currently serving as Chief Executive Officer and Vice Chair at CERo Therapeutics, Inc. since February 2024, Chris also holds positions as Senior Advisor at Espervita Therapeutics and Senior Business Advisor at both Altiibio and Dimension Inx. Additionally, Chris is an Advisor on the Health Care at Kellogg Advisory Board and has been a Board Member at PMDI since January 2012 and the Peter Michael Foundation since January 2010. Previous roles include Director at eFFECTOR Therapeutics, Inc. and Chief Executive Officer at Phoenix Biotech Acquisition Corp. Chris holds an MBA from Northwestern University's Kellogg School of Management and a Bachelor’s degree in Political Science and Government from Dartmouth College.